Donate

Oncolink Features

Find My Cancer Drug

Cancer Types / Miscellaneous/Other Diseases / Thymoma / NCI Resources

NCI CANCERLIT^® Search: Malignant Thymoma - July 2002

National Cancer Institute^®
Last Modified: July 1, 2002

Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.
[Non-invasive thymoma]
[A case of myasthenia gravis accompanied by large thymoma and anti-GAD antibody]
Encapsulated thymoma metastasizing to a pectoralis major muscle.
Images in pathology. Infarcted thymoma.
The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999.
[Clinico-morphological characteristic of the thymus gland changes in myasthenia and their surgical treatment]
[Thymoma complicated with miliary tuberculosis]
[Multimodality treatment outcome of invasive thymomas]

Table of Contents

1
UI - 11952859
AU - Pomplun S; Wotherspoon AC; Shah G; Goldstraw P; Ladas G; Nicholson AG
TI - Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.
SO - Histopathology 2002 Feb;40(2):152-8
AD - Department of Histopathology, Royal Brompton Hospital, London, UK.
AIMS: The histopathological features of some thymic neoplasms overlap with those of pulmonary squamous and large-cell undifferentiated carcinomas, and identification of the primary site may be difficult on routine staining. We have assessed a panel of antibodies that may help to distinguish between neoplasms from these two sites. METHODS AND RESULTS: Antibodies identifying cytokeratin 7 (CK7), CD5, CD10, CD1a and thyroid transcription factor-1 (TTF-1) were applied to a series of 20 thymic neoplasms (thymic carcinomas, atypical thymomas and thymomas), 10 primary squamous cell carcinomas of the lung and 10 large-cell undifferentiated carcinomas of the lung. Staining for TTF-1 was positive in 3/10 large-cell undifferentiated carcinomas, but negative in all other tumours. CD5 showed strong membranous staining in 3/6 thymic carcinomas and 1/14 thymomas, but only focal staining in 1/20 pulmonary carcinomas. CD1a was consistently positive in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 thymic carcinomas. CD1a stained dendritic cells in 7/20 pulmonary carcinomas, but did not stain lymphocytes. Staining for CK7 and CD10 did not aid in differentiating between a pulmonary or thymic origin of the tumour. CONCLUSION: Staining for TTF-1, CD5 and CD1a have potential use in distinguishing between pulmonary and thymic neoplasms.

2
UI - 11692817
AU - Clavijo-Montecinos I; Criales JL
TI - [Non-invasive thymoma]
SO - Gac Med Mex 2001 Sep-Oct;137(5):485-6

3
UI - 12080617
AU - Kitae S; Kawakami H; Matsuoka N; Etoh R; Nakamura S
TI - [A case of myasthenia gravis accompanied by large thymoma and anti-GAD antibody]
SO - Rinsho Shinkeigaku 2001 Nov;41(11):818-21
AD - Department of Neurology, Kurashiki Central Hospital.
A 61-year-old woman had repeated episodes of muscle weakness of face, neck and limbs for 18 years. She was diagnosed as having myasthenia gravis (MG) by the positive anti-acetylcholine receptor antibody and findings of electromyogram. Simultaneously, she was noticed to have diabetes mellitus with high titers of anti-glutamic acid decarboxylase (GAD) antibody. Magnetic resonance imaging showed a large thymoma. In spite of the improvement of MG after thymectomy, the insulin secretion slowly exacerbated during next two years. The clinical course of her disease was characteristic as slowly progressive insulin dependent diabetes mellitus (SPIDDM). She continued to have positive autoantibody against beta-cell of pancreas. Recently, anti-GAD antibody is detected in patients with SPIDDM and stiffman syndrome (SS) in high rate, and it is closely associated with the cause of these syndromes. The patient did not reveal the symptoms of SS. From the clinical course, MG and SPIDDM in this patient may be caused by a common underlying autoimmune abnormality resulting from the long presence of the thymoma. MG and SPIDDM may be derived from organ-specific autoimmunopathy from the defect of self-tolerance.

4
UI - 12073605
AU - Ohde Y; Yokose T; Yoshida J; Matsumoto T; Nagai K
TI - Encapsulated thymoma metastasizing to a pectoralis major muscle.
SO - Jpn J Thorac Cardiovasc Surg 2002 Jun;50(6):260-2
AD - Division of Thoracic Oncology, National Cancer Center Research Institute, East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
An extensive review of the literature suggests that ours is the first case of encapsulated thymoma metastasizing to a skeletal muscle. A 43-year-old man underwent thymothymectomy for encapsulated Masaoka's stage I thymoma. Four years after complete resection, the tumor metastasized to the left pectoralis major muscle. Although a few reports exist on encapsulated thymoma metastasizing to a distant site, the literature does not describe encapsulated thymoma metastasizing to a skeletal muscle insofar as we could find.

5
UI - 12075408
AU - Kuo TT
TI - Images in pathology. Infarcted thymoma.
SO - Int J Surg Pathol 2002 Apr;10(2):147
AD - Department of Pathology Chang Gung Memorial Hospital, Taipei, Taiwan.

6
UI - 12105313
AU - Somnier FE; Engel PJ
TI - The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999.
SO - Neurology 2002 Jul 9;59(1):92-8
AD - Laboratory of Neuroimmunology, Department of Neurology, The National Hospital (Rigshospitalet), Copenhagen, Denmark. Somnier@dadlnet.dk
OBJECTIVE: To estimate the incidence of elevated anti-titin antibodies titers and of thymomas in a population of patients with MG using various statistics and associations. METHODS: Extensive epidemiology, systematic measurement of anti-titin antibodies, and histologic assessment of thymomas according to the new World Health Organization classification. RESULTS: The mean annual incidence rate of MG per million population was 8.3. The analogous mean rate of thymomas was 2.0, out of which MG was encountered in about 20%. A thymoma was coexistent in 7% of the patients with MG. The finding of titin autoantibodies and the coexistence of thymomas were both associated with age at the appearance of MG. In patients with MG with a thymoma, the frequency of seropositivity was 68%, whereas acetylcholine receptor (AChR) autoantibodies were detected in all such sera. Titin autoantibody-positive sera were also anti-AChR antibodies positive. Further, all serum samples negative for anti-AChR antibodies were devoid of anti-titin antibodies. Titin autoantibodies were not detected in nonthymoma early-onset MG. CONCLUSION: Apart from MG with a thymoma, the finding of the titin autoantibodies was observed to be an exclusive feature of late-onset MG, the frequency being 55%. No data were found to suggest that patients with MG were more likely to present with thymic tumors than other patients exhibiting thymic neoplasia. In about 80%, such tumors in MG were composed of cortical cells. The concept of the anti-titin antibodies merely as a paraneoplastic marker in MG was not supported by these data.

7
UI - 11944269
AU - Peliukhovskii SV; Gonshcherovskii LIu; Kaspshik M
TI - [Clinico-morphological characteristic of the thymus gland changes in myasthenia and their surgical treatment]
SO - Klin Khir 2001 Dec;(12):29-30
Histological investigation of thymic gland was performed in 155 patients with various forms of myasthenia. Two variants of histological changes in thymic gland were revealed. In presence of the first variant performance of thymectomy was effective in 81.3% and in presence of the second--in 51%.

8
UI - 12073619
AU - Kisohara A; Takahashi N; Koya Y; Horie T
TI - [Thymoma complicated with miliary tuberculosis]
SO - Kekkaku 2002 May;77(5):415-9
AD - First Department of Internal Medicine, Nihon University School of Medicine, 30-1, Oyaguchi-Kamimachi, Itabashi-ku, Tokyo 173-0032, Japan. kisohara@med.nihon-u.ac.jp
We report a case of thymoma complicated with miliary tuberculosis. A 69-year-old woman was admitted to a hospital because of body weight loss, general fatigue, and dyspnea. Chest X-ray showed a small, diffuse granular shadows in both lungs. Biopsied-specimens from bone marrow and left pharynx revealed granuloma with both giant cells and caseous necrosis. The diagnosis of miliary tuberculosis was made. The patient was then transferred to our hospital. Both chest X-ray and computed tomography conducted on admission revealed a mass in the mediastinum as well as diffuse granular shadows in both lungs. We suspected a presence of thymoma. Anti-tuberculosis therapy was started, and extended thymectomy was performed. The diagnosis of thymoma was confirmed pathologically. Immunological analysis of peripheral blood lymphocytes was done before and after the operation. Negative conversion of PPD reaction was observed after thymectomy. Although the response of peripheral lymphocytes to phytohaemoagglutinin (PHA) and concanavalin A recovered after thymectomy, a marked decrease of the number of CD 4 T cells, a decrease of T helper 1 cells, a slight increase in the number of B cells and cells expressing natural killer cell-related surface markers were observed throughout the course of illness.

9
UI - 12089971
AU - Andriescu L; Buiuc AI; Dolinescu C; Dragomir C; Albulescu E
TI - [Multimodality treatment outcome of invasive thymomas]
SO - Rev Med Chir Soc Med Nat Iasi 2000 Apr-Jun;104(2):103-8
AD - Facultatea de Medicina, Clinica a III-a Chirurgie, Universitatea de Medicina si Farmacie Gr.T. Popa, Iasi.
The aim of the study was to analyze the progression of invasive thymomas associated with myasthenia gravis, after the resection and the progression of unresectable invasive thymomas with a combined chemoradiotherapy. The study was performed on two groups of patients: 8 patients with invasive thymomas and myasthenia gravis operated at the 3rd Surgical Clinic between 1986-1999; 4 patients with unresectable invasive thymomas treated at the Radiology-Oncology Clinic by combined chemoradiotherapy, between 1993-1998. The results are presented for each group of patients, separately. CONCLUSION: The best treatment of invasive thymomas is the multimodal one. The timing of each method was established based on the collaboration between surgeons, medical oncologists, radiotherapists and neurologists, depending on the characteristics of each patient.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink I wish u knew...

Dr. Mao talks about complementary and alternative medicine and the importance of being open about their use with cancer caregivers. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement